The Familial Amyloid Cardiomyopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Familial Amyloid Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Familial Amyloid Cardiomyopathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Familial Amyloid Cardiomyopathy and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Familial Amyloid Cardiomyopathy by eight companies/universities/institutes. The top development phase for Familial Amyloid Cardiomyopathy is phase iii with four drugs in that stage. The Familial Amyloid Cardiomyopathy pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Familial Amyloid Cardiomyopathy pipeline products market are: Alnylam Pharmaceuticals, Alexion Pharmaceuticals and BSIM Therapeutics.
The key targets in the Familial Amyloid Cardiomyopathy pipeline products market include Transthyretin.
The key mechanisms of action in the Familial Amyloid Cardiomyopathy pipeline product include Transthyretin Inhibitor with seven drugs in Filing rejected/Withdrawn. The Familial Amyloid Cardiomyopathy pipeline products include five routes of administration with the top ROA being Intravenous and five key molecule types in the Familial Amyloid Cardiomyopathy pipeline products market including Small Molecule, and Antisense RNAi Oligonucleotide.
Familial Amyloid Cardiomyopathy overview
Familial amyloid cardiomyopathy (FAC), or transthyretin amyloid cardiomyopathy (ATTR-CM), results from the aggregation and deposition of mutant and wild-type transthyretin (TTR) protein in the heart. TTR is usually circulated as a homo-tetramer; however, in FAC patients, TTR dissociates and misassembles into amyloid fibrils that are insoluble and resistant to degradation. Due to this resistance to degradation, when amyloid fibrils accumulate in the heart’s walls, specifically the left ventricle, causing rigidity that prevents the heart from properly relaxing and refilling with blood. This is called diastolic dysfunction and can further lead to heart failure.
For a complete picture of Familial Amyloid Cardiomyopathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
